Advanced SearchSearch Tips
Effects of Purslane Extract on Obesity and Diabetes in High-Fat Diet-Induced Obese Mice
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Effects of Purslane Extract on Obesity and Diabetes in High-Fat Diet-Induced Obese Mice
Kang, Kwang-Soon;
  PDF(new window)
The frequency of obesity has risen dramatically in recent years but only few safe and effective drugs are currently available. In addition, obesity can induce type 2 diabetes (T2DM), hyperlipidemia and fatty liver disease. Recently, protective effect of purslane extract (PE) on obesity has been reported, but little is known about the role and mechanism of PE in obesity. This study aimed to evaluate the effect of PE on obesity and diabetes in obese mice. In addition, the effect of PE was compared with anti-obesity and diabetes drugs. High-fat diet (HFD)-induced obese mice were treated for 8 weeks with drugs as follows: PE, orlistat, metformin, voglibose or pioglitazone. While PE mixed with normal diet did not have any effects on BW in non-obese mice, PE mixed with HFD significantly reduced BW gain, insulin resistance, and glucose intolerance, without affecting food intake and appetite in obese mice. The effect was comparable to the effects of anti-obesity and diabetes drugs. Furthermore, PE significantly increased the activity of hepatocellular anti-oxidant enzymes, leading to protection of liver from oxidative stress in obese mice. These results suggest that PE treatment may be a useful tool for preventing obesity and complication of obesity.
Purslane;Obesity;Type 2 diabetes;glucose tolerance;fatty liver;
 Cited by
M. Leonhardt, B. Hrupka and W. Langhans, "New approaches in the pharmacological treatment of obesity," Eur J Nutr, 38(1), pp. 1-13, Feb, 1999. crossref(new window)

S. Rossner, "Obesity: the disease of the twenty-first century," Int J Obes Relat Metab Disord, 26(Suppl 4), pp. 2-4, Dec, 2002.

AH. Mokdad, BA. Bowman, ES. Ford, F. Vinicor, JS. Marks and JP. Koplan, "The continuing epidemics of obesity and diabetes in the United States," JAMA, 286, pp. 1195-200, Sep, 2001. crossref(new window)

SE. Kahn, RL. Prigeon, and DK. McCulloch, et al, "Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function," Diabetes, 42, pp. 1663-72, Nov, 1993. crossref(new window)

M. Perley, DM. Kipnis, "Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects," Diabetes, 15, pp. 867-74, Nov, 1966. crossref(new window)

KS. Polonsky, BD. Given and E. Van Cauter, "Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects," J Clin Invest, 81, pp. 442-8, Feb, 1988. crossref(new window)

SE. Kahn, "The importance of beta-cell failure in the development and progression of type 2 diabetes," J Clin Endocrinol Metab, 86, pp. 4047-58, Sep, 2001.

J. Yan, LR. Sun, ZY. Zhou, YC. Chen, WM. Zhang and HF. Dai, et al, "Homoisoflavonoids from the medicinal plant Portulaca oleracea," Phytochemistry, 80, pp. 37-41, Aug, 2012. crossref(new window)

S. Mohanapriya, P. Senthilkumar, S. Sivakumar , M. Dineshkumar and CV. Subbhuraam, "Effects of copper sulfate and copper nitrate in aquatic medium on the restoration potential and accumulation of copper in stem cuttings of the terrestrial medicinal plant, Portulaca oleracea linn," Environ Monit Assess, 121, pp. 233-44, Oct, 2006. crossref(new window)

AN. Rasheed, FU. Afifi, M. Shaedah and MO. Taha, "Investigation of the active constituents of Portulaca oleraceae L. (Portulacaceae) growing in Jordan," Pak J Pharm Sci, 17, pp. 37-45, Jan, 2004.

MK. Uddin, AS. Juraimi, MS, Hossain, MA. Nahar, ME. Ali and MM. Rahman, "Purslane weed (Portulaca oleracea): a prospective plant source of nutrition, omega-3 fatty acid, and antioxidant attributes," ScientificWorldJournal, 10, pp. 1155, Feb, 2014.

R. Silva, IS. Carvalho, "vitro antioxidant activity, phenolic compounds and protective effect against DNA damage provided by leaves, stems and flowers of Portulaca oleracea (Purslane)," Nat Prod Commun, 9(1), pp. 45-50, Jan, 2014.

L. Liu, P. Howe, YF. Zhou, ZQ. Xu, C. Hocart and R. Zhan, "Fatty acids and beta-carotene in australian purslane (Portulaca oleracea) varieties," J Chromatogr A, 893(1), pp. 207-13, Sep, 2000. crossref(new window)

AP. Simopoulos, N Jr. Salem, "Purslane: a terrestrial source of omega-3 fatty acids," N Engl J Med, 315(13), pp. 833, Sep, 1986.

BC. Chan, XQ. Han, SL. Lui, CW. Wong, TB. Wang and DW. Cheung, et al, "Combating against methicillin-resistant Staphylococcus aureus - two fatty acids from Purslane (Portulaca oleracea L.) exhibit synergistic effects with erythromycin," J Pharm Pharmacol, 67(1), pp. 107-16, Jan, 2015. crossref(new window)

K. Chan, MW. Islam, M. Kamil, R. Radhakrishnan , MN. Zakaria, M. Habibullah, et al, "The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.) Celak," J Ethnopharmacol 73(3), pp. 445-51, Dec, 2000. crossref(new window)

O. Parry, JA. Marks and FK. Okwuasaba, "The skeletal muscle relaxant action of Portulaca oleracea: role of potassium ions," J Ethnopharmacol 40(3), pp. 187-94, Dec, 1993. crossref(new window)

AN. Rashed, FU. Afifi and AM. Disi, "Simple evaluation of the wound healing activity of a crude extract of Portulaca oleracea L. (growing in Jordan) in Mus musculus JVI-1," J Ethnopharmacol, 88(2-3), pp. 131-6, Oct, 2003. crossref(new window)

HM Jr. Abdalla, "Purslane extract effects on obesity-induced diabetic rats fed a high-fat diet," Malays J Nutr, 16(3), pp. 419-29, Dec, 2010.

MI. El-Sayed MI, "Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy," J Ethnopharmacol, 137(1), pp. 643-51, Sep, 2011. crossref(new window)

B. Chen, H. Zhou, W. Zhao, W. Zhou, Q. Yuan and G. Yang, "Effects of aqueous extract of Portulaca oleracea L. on oxidative stress and liver, spleen leptin, $PAR{\alpha}$ and FAS mRNA expression in high-fat diet induced mice," Mol Biol Rep, 39(8), pp. 7981-8, Aug, 2012. crossref(new window)

JM. Miles, L. Leiter, P. Hollander, T. Wadden, JW. Anderson M. Doyle, et al, "Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin," Diabetes Care, 25(7), pp. 1123-8, Jul, 2002. crossref(new window)

M. Negishi, K. Shimomura, P. Proks, Y. Shimomura and M. Mori, "Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients," Br J Clin Pharmacol, 66(2), pp. 318-9, Aug, 2008. crossref(new window)

P. Sumithran and J. Proietto, "Benefit-risk assessment of orlistat in the treatment of obesity," Drug Saf, 37(8), pp. 597-608, Aug, 2014. crossref(new window)

B. Goke, H. Fuder, G. Wieckhorst, U. Theiss , E. Stridde,T. Littke, et al, "Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve," Digestion, 56(6), pp. 493-501, 1995. crossref(new window)

J. Chilcott, P. Tappenden, ML. Jones and JP. Wight, "A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus," Clin Ther, 23(11), pp. 1792-823, Nov, 2001. crossref(new window)